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Introduction
Mostly chronic course of the interstitial lung diseases
leads to pulmonary fibrosis and chronic respiratory
failure. The process of interstitial inflamation goes flu-
ently from alveolitis, through  granuloma formation, to
irreversible fibrosis.
In the last few years pneumoproteins (e.g. surfac-
tant proteins) are considered to be markers of intersti-
tial inflammation. In patients with idiopathic pul-
monary fibrosis (IPF), it has been demonstrated that
histological pattern of usual interstitial pneumonia
(UIP) is related to low concentration of surfactant pro-
tein A (SP-A) and D (SP-D) in bronchoalveolar lavage
(BAL) [1] and to high serum concentration of SP-A
and SP-D. Serum concentration of SP-D is higher in
patients with sarcoidosis than in healthy volunteers
[1,2]. Similarly, the more active interstitial process in
patients with hypersensivity pneumonitis (HP), the
higher SP-D serum concentrations [3].
BAL concentration of Clara cell protein (CC-16) is
decreased, and phospholipase A2 activity is increased
in patients with IPF in comparison with healthy sub-
jects [4]. It has been shown that in sarcoidosis serum
CC-16 concentration is increased [5,6], but CC-16
BAL concentration  is similar to levels observed in
healthy subjects.
This study was designed to determine the useful-
ness of determination biochemical markers (SP-D,
CC-16, IL-10) in BAL derived from patients with sar-
coidosis, IPF and HP. Another aim of this  study  was
to answer the question whether SP-D, CC-16 and IL-




Vol. 47, No. 2, 2009
pp. 225-230
Concentration of surfactant protein D, Clara cell protein
CC-16 and IL-10 in bronchoalveolar lavage (BAL) 
in patients with sarcoidosis, hypersensivity pneumonitis
and idiopathic pulmonary fibrosis
Wojciech Kucejko, El¿bieta Chyczewska, Wojciech Naumnik, Maria Ossoliñska
Department of Lung Diseases and Tuberculosis, Medical University of Bia³ystok, Bia³ystok, Poland
Abstract: The process of interstitial inflammation, often chronic, goes fluently from alveolitis through granuloma forma-
tion to irreversible fibrosis and lung remodeling. Eventually, the loss of functional alveolar units leads to chronic respirato-
ry failure. The pneumoproteins (e.g. SP-D, CC-16) are considered to be markers of interstitial inflammation. We measured
BAL concentration of SP-D, CC-16 and IL-10 in patients with sarcoidosis (27), IPF (7) and HP (9). The level of each mark-
er was determined by ELISA specific kit. We found the highest SP-D and CC-16 BAL concentration in patients with the III
stage of sarcoidosis (96,67 ng/ml and 31,78 ng/ml, respectively). The lowest SP-D concentration was observed in patients
with IPF (76,49 ng/ml), and the lowest CC-16 concentration in patients with HP (21,39 ng/ml). The differences were not
statistically significant. In the group of the III stage of sarcoidosis higher SP-D levels were related to higher BAL cytosis
and higher percentage of BAL neutrophils, just the opposite as in the IPF and HP group. In the III stage of sarcoidosis and
HP, the lower SP-D levels, the lower FEV1 and VC values. The results show, that in acute interstitial inflammation with
larger parenchyma engagement (III stage of sarcoidosis) the levels of SP-D were higher then in chronic interstitial inflam-
mation (IPF).
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Materials  and  methods
Patients. Bronchoalveolar lavage fluid was harvest from from 
43 patients hospitalized and diagnosed in Pulmonary Department
(Medical University of Bia³ystok, Bia³ystok, Poland) for suspi-
cion of ILD. There were 27 patients with sarcoidosis (13 in II
stage and 14 in III stage of sarcoidosis) 7 patients with IPF and 9
with HP. Patients did not present any signs of infection, or chron-
ic lung disease. They were not treated with corticosteroids,
immunosuppresive agents or any other drugs known as a poten-
tial ILD couse.
Patients were divided into 4 groups: group I – II stage of sar-
coidosis, group II – III stage of sarcoidosis, group III – IPF, group
IV – hypersensivity pneumonitis.
In every case laboratory tests (plasma ACE activity, plasma Ca
concentration, Ca concentration in 24-hours urine collection),
chest X-ray, chest high resolution computed tomography (HRCT),
bronchofiberoscopy and BAL, spirometry, capillary blood gasom-
etry, EKG, USG of abdominal organs, RT-23 were performed.
The diagnosis of sarcoidosis was made on the basis of histo-
logical presence of noncaseating granulomas, physical signs, bron-
choscopic pattern, BAL, x-ray and HRCT. Radiological staging of
sarcoidosis was carried out according to American Thoracic Soci-
ety and European Respiratory Society criteria [7]. The disease
activity was assessed on the grounds of BAL abnormalities, ACE
plasma activity, Ca plasma and 24-hours urine colletion concentra-
tion. We also assessed organ involvement (heart, liver, spleen, kid-
neys and ocular involvement) in the course of sarcoidosis. Histo-
logical samples were collected during mediastiniscopy (4 cases),
transbronchial lung biopsy (11 cases), bronchial mucus biopsy 
(6 cases), transbronchial lymph nodes biopsy (5 cases) and surgi-
cal lung biopsy  (1 case).
Hypersensitivity pneumonitis was diagnosed according to HP
diagnostic criteria [8]. In 6 cases transbronchial lung biopsy was
performed to collect histological samples. Histological examina-
tions revealed inflammatory cells infiltrations, and in one case,
interalveolar septa fibrosis. In every case serological tests were
performed to assess the presence of specific precipitins in serum.
Bronchofiberoscopy. Bronchoscopy was performed using Olym-
pus BF-1T30 bronchofiberoscope. The patients were premedicated
with midazolam 5 mg and atropine 0.5 mg, followed by local anes-
thesia of upper and lower airways with 2% lidocaine solution.
Bronchoalveolar lavage (BAL). BAL was carried out according
to criteria of ERS [9,10]. The bronchofiberoscope was inserted into
the middle lobe or into the left lung lingual, alternatively. Lavage
with 200 ml of 0.9% NaCl sterile solution (37°C) was carried out
by sequential instillation of four 50 ml aliquots of saline. The BAL
fractions were retrieved by gentle suction. The fluid recovery was
calculated as the percentage of the instilled volume. The material
was immediately sent to the laboratory. The BAL material was cen-
trifuged (1000 rpm, 10 min.). The total cell count and cell viabili-
ty were calculated, as described before.  The BAL filtrate samples
were stored at -20°C until assay performance.
The level of each marker was measured by commercially avail-
able specific kits according to the protocols provided by the man-
ufacturer. SP-D, CC-16 and IL-10 BAL concentration were deter-
mined by ELISA method.  SP-D and CC-16 kits came from
BioVendor, Brno, Czech Republic. The test sensitivity was 
0.5 ng/ml. IL-10 kit came from R&D Systems, Minneapolis, USA.
The test sensitivity was <3.9 pg/ml. The assays were performed
simultaneously, after samples defrosting. For each patient's sample
two assays were performed, and the mean value was considered as
the final value.
Statistical analysis. All measured values were presented as medi-
ans ± SEM (due to nonparametric distribution of values). Qualita-
tive traits were presented as quantitative-percentage distribution.
The Mann-Whitney U-test was used to compare the data obtained
in analysed groups. The Spearman's rank correlation coefficient rs
was applied to test the correlation between two random variables.
P-values <0.05 were considered as statistically significant. P-val-
ues >0.05 and <0.1 were considered to be within statistical signif-
icance limit.
Results
Basic patients and groups characteristics are shown in
Table 1. In group III (patients with IPF) the VC values
were significantly lower than in group I (patients with
II stage of sarcoidosis) and than in group II (patients
with III stage of sarcoidosis) (p=0.014 and p=0.002,
respectively). The highest mean FEV1 value 
(97.92% expected) was found in group I, and the low-
est (76.99% expected) – in group III. The highest mean
VC value (96.83%) was found in group II, and the
lowest (70.23%) in group III. The serum ACE activity
(73.15 U/l) was the highest in patients with II stage of
sarcoidosis.
We found the highest mean BAL cytosis in
patients with II stage of sarcoidosis and in patients
with hypersensivity pneumonitis – in both groups 1.5
× 106 / ml. The lowest BAL cytosis (1.43 × 106 / ml)
was present in patients with IPF. In group I and II we
found statistically significant higher BAL limphocy-
tosis than in group III (p=0.015 and p=0.026, respec-
tively). There was a higher neutrophil BAL percent-
age in patients with IPF than in patients with II stage
of sarcoidosis (p=0.008) and in patients with hyper-
sensivity pneumonitis (p=0.032). Similarly, in IPF
group the BAL percentage of eosinophils was higher
than in group I, II and IV (p=0.021, p=0.014 and
p=0.002, respectively).
The mean values of capillary blood gasometry were
close to normal, there were no significant differences
between groups.
We observed the highest SP-D BAL concentration
in patients with the III stage of sarcoidosis 
(96.67 ng/ml), and the lowest in patients with IPF
(76.49 ng/ml). Similarly, the BAL concentration of
Clara cell protein was the highest in patients with III
stage of sarcoidosis (31.78 ng/ml), and the lowest in
patients with hypersensivity pneumonitis (21.39 ng/ml)
(Fig. 1). The concentration differences were not statis-
tically significant.
The highest BAL concentration of IL-10 was
found in patients with IPF (2.04 pg/ml); the lowest –
in patients with hypersensivity pneumonitis (1.68
pg/ml). In IPF group IL-10 concentration was signifi-
cantly higher than in the group of patients in III stage
of sarcoidosis (p=0.02) and in the HP group
(p=0.023). In comparison to patients with II stage of
sarcoidosis, the difference was within statistical sig-
nificance limit (p=0.08).
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Correlations in group I (II stage of sarcoidosis)
Higher BAL SP-D concentrations were related to
lower VC values (p=0.07), FEV1 values and lower
lymphocytes percentage in BAL (p=0.09). Higher
BAL SP-D levels were related to higher percentage of
BAL neutrophils (p=0.076), and to lower BAL cyto-
sis. We found statistically significant correlation
between BAL CC-16 concentration and plasma ACE
activity (Fig. 2).
Correlations in group II (III stage of sarcoidosis)
We found that the higher IL-10 concentrations, the
higher SP-D concentrations (p=0.056; Fig. 3). The
same relationship was observed between IL-10 and
CC-16 concentration (p=0.048; Fig. 4). The important
thing is that low SP-D BAL concentrations were relat-
ed to low FEV1 and VC values. The second depend-
ence was statistically significant (p=0.038; Fig. 5). In
this group high SP-D concentration was associated
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Table 1. Baseline patients characteristics
HP – hypersensivity pneumonitis; IPF – idiopathic pulmonary fibrosis; FEV1 – forced expiratory volume in one second; VC – vital capacity; BAL
– broncho-alveolar lavage; ACE – agiotensin converting enzyme
Fig. 1. BAL concentration of SP-D,
CC-16 and IL-10 in different groups.
SP-D – surfactant protein D; CC-16 –
Clara cell protein; BAL – broncho-
alveolar lavage 
with high BAL cytosis and high BAL percentage of
lymphocytes, neutrophils and eosinophils. We also
found that high SP-D level was related to low pO2
values.
Correlations in group III (IPF)
High CC-16 concentration was related to lower BAL
cytosis and to lower BAL neutrophils percentage. In
this case there was a higher BAL percentage of lym-
phocytes and eosinophils. High SP-D concentration
was related to lower BAL percentage of lymphocytes,
neutrophils and eosinophils. We also found, that high-
er CC-16 concentrations were related to higher pO2
values and to a higher blood O2 saturation. In this
group we did not find any correlations between BAL
concentration of SP-D nor IL-10 and the lung function
tests abnormalities. But high CC-16 concentrations
were related to low VC values. We observed, that the
higher SP-D levels, the higher pCO2 and the lower pO2
in capillary blood gasometry. According to our expec-
tations, higher IL-10 levels were related to lower BAL
cytosis and to lower percentages of neutrophils and
eosinophils.
Correlations in group IV
(Hypersensivity pneumonitis)
Higher SP-D concentration was related to higher IL-10
and lower CC-16 levels. Similarly, lower SP-D levels
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Fig. 5. Relationship between VC and BAL concentration of SP-D
(group II). VC – vital capacity; SP-D – surfactant protein D; BAL
– bronchoalveolar lavage; w.n. – percentage of expected value
Fig. 2. Relationship between BAL concentration of CC-16 and
serum activity of ACE in group I. ACE – angiotensin converting
enzyme; CC-16 – Clara cell protein; BAL – bronchoalveolar
lavage 
Fig. 3. Relationship between BAL concentrations of SP-D and IL-
10 in group II. SP-D – surfactant protein D; BAL – bronchoalveo-
lar lavage; IL-10 – interleukin 10
Fig. 4. Relationship between BAL concentrations of IL-10 and
CC-16 in group II. IL-10 – interleukin 10; CC-16 -Clara cell pro-
tein; BAL – broncholaveolar lavage
were associated with lower FEV1 and VC levels, as in
group II. Moreover, the higher SP-D concentration, the
lower BAL cytosis and the lower BAL percentage of
lymphocytes, neutrophils and eosinophils. We also
observed that, the higher SP-D level, the higher serum
ACE activity (not statistically significant).
Discussion
Bronchoalveolar lavage (BAL) allows researchers to
investigate the processes going on in alveoli. Both cel-
lular and liquid BAL components can be studied 
(e.g. pneumoproteins) [6,11,12].
There are not many publications on SP-D BAL
concentrations in healthy volunteers. Mean SP-D con-
centration according to different authors ranges from
about 0.9 to 1.3 mg/l [1,13]. Mean CC-16 concentra-
tion in BAL from healthy volunteers is about 0.1 to 
3.6 mg/l [5,14,15,16]. The differences might result
from usage of different monoclonal antibodies and dif-
ferent standards by research centers. It concerns both
patients and healthy volunteers [7].
According to Ishii et al. [18] inflammation process
engaging alveoli results in destruction of II type pneu-
mocytes and other cells lining both alveoli and bron-
chioles. Above-mentioned cell contents (e.g. surfactant
proteins) is released into alveoli lumen. Protracting
inflammation process leads to granuloma formation
and to partial regenerating of alveolar lining cells.
Alveolar type II cells become hyperplastic.  At the
same time fibroblast migration starts, and subsequent-
ly extracellular matrix deposition begins together with
interstitial fibrosis. This process might lead to lung
parenchyma remodeling and to developing "honey-
comb change" on HRCT scans. Then, surfactant pro-
teins concentration decreases. It happens because of
both reduced synthesis and increased phagocytosis by
alveolar macrophages [18,19].
In the course of sarcoidosis  and  IPF  higher  serum
levels of CC-16 were observed. Little is known on CC-
16 concentration in BAL fluid. To date is has been
shown that in BAL from smokers the level of this pro-
tein is decreased. The reason for this observation
might be the decreased number of Clara cells
[16,20,21]. More over, in healthy subjects there is a
higher BAL concentration of CC-16 than in patients
with IPF, in patients with asbestosis and than in sub-
jects with ARDS [22,23,24]. In those cases the most
reasonable explanation of decreased CC-16 level was
unfavourable course of the disease.
In this study, we compared the value of SP-D, CC-
16 and IL-10 as BAL markers of disease activity in
different ILDs – sarcoidosis, idiopathic pulmonary
fibrosis and hypersensivity pneumonitis. Mean BAL
levels that we found were lower than published by
other authors. We observed the highest SP-D concen-
tration in patients with III stage of sarcoidosis. Lower
SP-D concentrations were related to higher VC values
in patients with II stage of sarcoidosis, in contrast
with patients with III stage of sarcoidosis. In both
groups mean VC values were close to normal. In
agreement to previous studies [25], higher levels of
SP-D were related to higher BAL cytosis and higher
percentages of BAL lymphocytes. In this study, the
higher CC-16 level, the higher ACE serum activity.
Other authors, e.g. Janssen [2], determined serum
pneumoproteins concentrations, and compared their
results with those from healthy subjects. Such studies
demonstrated higher concentrations of SP-D and CC-
16 in both sarcoidosis and IPF as compared to healthy
volunteers. The more lung parenchyma involvement
in sarcoidosis, the higher concentrations of studied
proteins [2,25].
Previous studies [1,3,18] demonstrated similar
findings to ours for SP-D in IPF. In IPF in contrast
with the III stage of sarcoidosis, higher levels of SP-D
were related to lower BAL percentage of lymphocytes.
In might result from different pathogenesis of the
above-mentioned diseases.
In this study we demonstrated the reverse correla-
tion between SP-D and CC-16. To our knowledge
there are no studies comparing BALF concentration of
these pneumoproteins in patients with IPF. In the
course of idiopathic pulmonary fibrosis lung
parenchyma remodeling develops. It might be the rea-
son for decreased number of Clara cells, and in conse-
quence the reason for low CC-16 BALF concentration.
Higher SP-D, CC-16 and IL-10 concentrations
were related to lower BAL percentage of lymphocytes,
neutrophils and eosinophils. These findings are in
agreement with expectations, because of the anti-
inflammatory properties of studied pneumoproteins.
But the recent data show no evidence of  inflammation
etiology in the pathogenesis of IPF [26,27]. The latest
theory describes repeated episodes of destruction of
lung epithelium and abnormal reconstructive process-
es leading to fibrinogen deposition in the extracellular
space [28]. It seems that different intensification of
typical histopathological changes in IPF (alveolitis,
fibroblast foci separated by normal lung interstitium,
foci of fibrosis) might be the reason for discrepancy in
recent reports [17].
We demonstrated the lowest concentrations of CC-
16 and IL-10 in patients with hypersensivity pneu-
monitis. In this group SP-D levels were higher than in
IPF group and lower than in both sarcoidosis groups.
Higher SP-D levels, similarly to IPF, were related to
lower CC-16 levels. In the course of hypersensivity
pneumonitis decreased number of Clara cells accom-
panied by low levels of CC-16 might be also observed.
In our HP group there were patients with acute, suba-
cute and chronic form of the disease. Similarly to IPF
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patients, we found in HP that higher SP-D concentra-
tions were related to lower BAL cytosis, lower BAL
percentage of lymphocytes, neutrophils and
eosinophils. Despite different pathogenesis, the reason
for the above-mentioned relationships seems to be the
same – anti-inflammatory properties of this protein. In
acute hypersensivity pneumonitis with active granulo-
ma formation process higher SP-D concentrations
related to higher ACE serum activity, just as in sar-
coidosis.
In conclusion, we found higher level of SP-D in
BAL fluid in active interstitial inflammation with larg-
er parenchyma engagement (III stage of sarcoidosis),
than in chronic stage of interstitial inflammation (IPF).
Moreover, we found  the highest concentration of  CC-
16 in patients with III stage of sarcoidosis, suggesting
destruction of Clara cells. Because of the small num-
ber of patients in each group further studies on pneu-
moproteins focusing on their role in the pathogenesis
of ILDs and in pulmonary fibrosis are necessary.
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